Kenneth A. Foon

Q: What Schools Are Affiliated With Kenneth A. Foon

Kenneth A. Foon is affiliated with the following schools: University of Kentucky, Stanford University, California South Bay University, University of Washington, University of Pittsburgh

Kenneth A. Foon's AcademicInfluence.com Rankings

Kenneth A. Foon

Medical

#2272

World Rank

#2683

Historical Rank

Oncology

#131

World Rank

#135

Historical Rank

medical Degrees

Kenneth A. Foon

Philosophy

#6629

World Rank

#9693

Historical Rank

Logic

#3771

World Rank

#4979

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Kenneth A. Foon's Degrees

Doctorate Medicine University of California, San Francisco
PhD Radiation Oncology University of California, San Francisco

Why Is Kenneth A. Foon Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Kenneth A. Foon's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. (1998) (1726)
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. (1997) (1245)
Immunologic classification of leukemia and lymphoma. (1986) (790)
Flow cytometric immunophenotyping for hematologic neoplasms. (2008) (599)
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma (1997) (572)
Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. (1985) (538)
Surface markers on leukemia and lymphoma cells: recent advances. (1982) (433)
Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group (1988) (399)
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. (2004) (322)
Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. (1984) (285)
Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. (1984) (264)
Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. (1997) (258)
Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia (2009) (255)
Chronic lymphocytic leukemia: new insights into biology and therapy. (1990) (249)
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. (2004) (224)
Biological response modifiers: the new immunotherapy. (1989) (212)
Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration. (1984) (193)
Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. (2009) (190)
IDEC-C 2 B 8 ( Rituximab ) Anti-CD 20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin ’ s Lymphoma (1997) (186)
T gamma-lymphoproliferative disease and related disorders in humans and experimental animals: a review of the clinical, cellular, and functional characteristics (1984) (182)
Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. (1984) (178)
Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. (1999) (169)
A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. (1982) (157)
Chronic lymphocytic leukemia. Recent advances in biology and treatment. (1985) (153)
Response to 2'-deoxycoformycin after failure of interferon-alpha in nonsplenectomized patients with hairy cell leukemia. (1986) (151)
Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. (1995) (151)
Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic results. (1986) (151)
The role of recombinant interferon alfa‐2a in the therapy of cutaneous t‐cell lymphomas (1986) (146)
Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. (2000) (138)
Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. (1997) (136)
Intensive chemotherapy for acute myelogenous leukemia. (1981) (129)
Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. (1986) (118)
The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. (2006) (118)
Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia. (1981) (118)
Immunologic classification of lymphocytic leukemias based on monoclonal antibody-defined cell surface antigens. (1982) (112)
Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. (1985) (109)
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients (2017) (104)
Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma (2008) (103)
Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen. (1990) (98)
Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. (1998) (97)
Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors (2009) (97)
Interferon‐α therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia (1992) (90)
Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain (1998) (89)
Kinetic model for the biodistribution of an 111In-labeled monoclonal antibody in humans. (1987) (85)
U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: medical indications. (1997) (84)
Type 1‐polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia (2008) (83)
Effect of antibody dose on the imaging and biodistribution of indium-111 9.2.27 anti-melanoma monoclonal antibody. (1988) (82)
Alpha interferon in the treatment of hematologic malignancies. (1986) (82)
Controversies in the therapy of acute myelogenous leukemia. (1982) (79)
Monoclonal antibodies reactive with acute myelogenous leukemia cells. (1981) (78)
Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. (1988) (78)
Determination of the optimal human cell lines for development of human hybridomas. (1983) (77)
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. (2017) (77)
Selective antitumor effect on L10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal antibody to a hepatoma-associated antigen. (1984) (76)
Guinea pig line 10 hepatocarcinoma model: characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain. (1983) (76)
Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. (1987) (72)
T65 antigen modulation in a phase I monoclonal antibody trial with chronic lymphocytic leukemia patients. (1984) (72)
Genetic Relatedness of Lymphoid Malignancies: Transformation of Chronic Lymphocytic Leukemia as a Model (1993) (68)
The antigenic characteristics of hematopoietic stem cells. (1981) (68)
Biology of chronic lymphocytic leukemia. (1987) (65)
Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. (1997) (65)
PROLONGED SURVIVAL IN ACUTE MYELOGENOUS LEUKAEMIA WITHOUT MAINTENANCE CHEMOTHERAPY (1984) (64)
Anti-idiotype vaccine against cancer. (2000) (62)
A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study (2014) (57)
Recombinant leukocyte A interferon in advanced breast cancer. Results of a phase II efficacy trial. (1983) (57)
Atypical tumor lysis syndrome in a patient with T cell lymphoma treated with recombinant leukocyte interferon. (1984) (57)
Dual B and T markers in acute and chronic lymphocytic leukemia. (1980) (56)
Increased growth of eyelashes in a patient given leukocyte A interferon. (1984) (56)
2-Chlorodeoxyadenosine-Induced Complete Remissions in Langerhans-Cell Histiocytosis (1994) (55)
Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody. (1998) (55)
Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. (2012) (54)
Intratumor localization of monoclonal antibody in patients with melanoma treated with antibody to a 250,000-dalton melanoma-associated antigen. (1985) (51)
Localization of 111In- and 125I-labeled monoclonal antibody in guinea pigs bearing line 10 hepatocarcinoma tumors. (1983) (49)
Recent advances in the immunologic classification of leukemia. (1986) (49)
Acute myelogenous leukemia: morphologic classification and response to therapy. (1979) (49)
Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2. (1997) (49)
Fate of gamma-interferon-activated killer blood monocytes adoptively transferred into the abdominal cavity of patients with peritoneal carcinomatosis. (1987) (48)
A phase I trial of recombinant gamma interferon in patients with cancer (2004) (47)
Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2. (1998) (46)
Interferon-alpha therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia. (1992) (46)
IMAGING OF T-CELL LYMPHOMA BY RADIOLABELLED MONOCLONAL ANTIBODY (1984) (46)
Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression. (2001) (45)
A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. (1988) (45)
T gamma-lymphoproliferative disease and related disorders in humans and experimental animals: a review of the clinical, cellular, and functional characteristics. (1984) (44)
Counterpoint. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine (2000) (44)
Biodistribution, pharmacokinetic, and imaging studies with 186Re-labeled NR-LU-10 whole antibody in LS174T colonic tumor-bearing mice. (1990) (44)
Approved monoclonal antibodies for cancer therapy. (2008) (44)
Lymphokines, monoclonal antibodies, and other biological response modifiers in the treatment of cancer (1984) (44)
The role of immunotherapy in acute myelogenous leukemia. (1983) (43)
Immune markers in hematologic malignancies. (1991) (42)
Dendritic Cells Pulsed with an Anti-Idiotype Antibody Mimicking Carcinoembryonic Antigen (CEA) Can Reverse Immunological Tolerance to CEA and Induce Antitumor Immunity in CEA Transgenic Mice (2004) (41)
Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant (2008) (41)
Serotonin-induced production of a monocyte chemotactic factor by human peripheral blood leukocytes. (1976) (41)
Colorectal cancer as a model for immunotherapy. (1999) (40)
Therapy of acute myelogenous leukemia. (1992) (39)
Are solid tumor anti-idiotype vaccines ready for prime time? Commentary re: U. Wagner et al., Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin. Cancer Res., 7: 1154-1162, 2001. (2001) (39)
Relationship of the clinical response and binding of recombinant interferon alpha in patients with lymphoproliferative diseases. (1986) (38)
Immunologic classification of acute lymphoblastic leukemia. Implications for normal lymphoid differentiation. (1980) (38)
Approved monoclonal antibodies for cancer therapy (2008) (37)
Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen. (1995) (37)
Guinea pig line 10 hepatocarcinoma model for monoclonal antibody serotherapy: in vivo localization of a monoclonal antibody in normal and malignant tissues. (1983) (37)
Interferon gamma augments Lym-1-dependent, granulocyte-mediated tumor cell lysis. (1990) (37)
Interferon therapy of non‐Hodgkin's lymphoma (1987) (36)
Immunologic defects in young male patients with hepatitis-associated aplastic anemia. (1984) (35)
The anti-idiotype vaccines for immunotherapy. (2001) (34)
Murine monoclonal anti‐idiotypic antibody as a surrogate antigen for human Her‐2/neu (2001) (34)
Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules. (2005) (34)
Anti-idiotype antibody vaccine therapies of cancer. (2002) (34)
Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity. (2003) (33)
Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials (2017) (33)
Evening administration of alpha interferon. (1985) (32)
Production of large quantities of human immunoglobulin in the ascites of athymic mice: implications for the development of anti-human idiotype monoclonal antibodies. (1984) (31)
Therapy of acute myelogenous leukemia. (1992) (31)
Anti-idiotype antibody vaccine therapy for cancer (2002) (30)
Recombinant interferon alfa‐2a, an active agent in advanced cutaneous t‐cell lymphomas (1987) (30)
Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen (2003) (29)
Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2 (2000) (29)
Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. (2007) (29)
Heterogeneity in a lymphoid tumor: coexpression of T and B surface markers. (1982) (28)
Immunolymphoscintigraphy and the dose dependence of 111In-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma. (1987) (28)
Alpha interferon treatment of low-grade B-cell non-Hodgkin's lymphomas, cutaneous T-cell lymphomas, and chronic lymphocytic leukemia. (1986) (28)
Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in FL from 5,225 Patients on 13 Clinical Trials. (2021) (27)
Leukemia of T-helper lymphocytes: clinical and functional features. (1981) (27)
Human alveolar macrophages express Ia-like antigens. (1981) (27)
Induction of human breast cancer-specific antibody responses in cynomolgus monkeys by a murine monoclonal anti-idiotype antibody. (1995) (27)
A preliminary Phase I trial of partially purified interferon-gamma in patients with cancer. (1984) (27)
A phase I evaluation of poly(I,C)-LC in cancer patients. (1985) (26)
Adjuvant immunotherapy for melanoma and colorectal cancers. (2001) (26)
CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice (2006) (26)
Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma (2015) (26)
Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors. (1990) (25)
Detection of two distinct malignant B cell clones in a single patient using anti-idiotype monoclonal antibodies and immunoglobulin gene rearrangement. (1985) (25)
Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients. (2017) (25)
Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias (2012) (25)
Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma. (1990) (24)
Flow cytometry: recent advances in diagnosis and monitoring of leukemia. (1997) (24)
Overview of monoclonal antibodies in the diagnosis and therapy of cancer. (1991) (24)
Acute myelogenous leukemia heteroantisera. (1980) (24)
Antigen mimicry by an anti-idiotypic antibody single chain variable fragment. (1998) (23)
Anti-idiotype monoclonal antibodies as vaccines for human cancer. (1991) (23)
Changing paradigms in the treatment of chronic lymphocytic leukemia (2010) (23)
Use of the anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. (2003) (22)
Clinical significance of monoclonal proteins in chronic lymphocytic leukemia. (1992) (22)
The generation of monoclonal anti-idiotype antibodies to human B cell-derived leukemias and lymphomas. (1985) (22)
Renal Cell Carcinoma Treated with Continuous‐Infusion Interleukin‐2 with Ex Vivo‐Activated Killer Cells (1992) (22)
Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu (2007) (22)
Tumor associated antigen (TAA) mimicry and immunotherapy of malignant diseases from anti-idiotypic antibodies to peptide mimics. (2001) (21)
Posttransfusion hepatitis in acute myelogenous leukemia. Effect on survival. (1980) (21)
Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients (2009) (20)
Anti‐idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen (2006) (20)
Biological and Hormonal Therapies of Cancer (1998) (20)
Idiotypic antibody immunotherapy of cancer (1994) (20)
Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL). (2017) (20)
MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma. (2019) (19)
Chronic leukemias: oncogenes, chromosomes, and advances in therapy. (1986) (19)
Monoclonal antibody therapy in malignant melanoma: factors effecting in vivo localization. (1987) (18)
Chronic lymphoid leukemias: Recent advances in biology and therapy (1995) (18)
Recombinant alpha interferon in retreatment of two patients with pulmonary lymphoma. Dramatic responses with resolution of pulmonary complications. (1984) (18)
Construction and characterization of a chimeric fusion protein consisting of an anti-idiotype antibody mimicking a breast cancer-associated antigen and the cytokine GM-CSF. (1999) (18)
Biological therapy of cancer (2005) (18)
Preclinical evaluation in nonhuman primates of an anti-idiotypic antibody that mimicks the carcinoembryonic antigen. (1995) (18)
Novel Therapies for Aggressive B-Cell Lymphoma (2012) (18)
Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells. (2010) (17)
Current and future uses of recombinant interferon alpha in the treatment of low‐grade non‐Hodgkin's lymphoma (1987) (17)
Immunomodulatory effects of poly(I,C)-LC in cancer patients. (1985) (17)
Light chain disease associated with the hyperviscosity syndrome (1987) (17)
Immunologic classification of childhood acute lymphocytic leukemia (1981) (17)
Localization and imaging with radioiodine-labeled monoclonal antibodies in a xenogeneic tumor model for human B-cell lymphoma. (1988) (16)
Anti-idiotype antibodies as potential therapeutic agents for human breast cancer. (1994) (16)
Monoclonal Antibody Therapy of Cancer: Preclinical Models and Investigations in Humans (1986) (16)
Phase II Trial of Abbreviated CHOP-Rituximab Followed by 90Y Ibritumomab Tiuxetan (Zevalin) and Rituximab in Patients with Previously-Untreated Follicular Non-Hodgkin Lymphoma (NHL). (2005) (15)
Shared idiotype expression by chronic lymphocytic leukemia and B-cell lymphoma. (1990) (15)
Antiidiotype (Ab2) Vaccine Therapy for Cutaneous T‐Cell Lymphoma a (1993) (15)
Analysis of the systemic corticosteroid sensitivity of patients with primary open-angle glaucoma. (1977) (15)
Acute myeloid leukaemia: recent advances in therapy. (1986) (15)
Acute myelogenous leukemia: current status of therapy in adults. (1984) (14)
Phase 1 Dose Escalation Study of TRU-016, An Anti-CD37 SMIP™ Protein In Relapsed and Refractory CLL (2010) (14)
Demonstration of macrophage chemotactic factors in the aqueous humor during experimental immunogenic uveitis in rabbits (1976) (14)
The B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia (CLL) cells. (2011) (13)
MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R2) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma (2016) (13)
Alpha-interferon treatment of cutaneous T cell lymphoma and chronic lymphocytic leukemia. (1986) (12)
Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease (2007) (12)
Monoclonal Antibody Therapy of Human Cancer (2012) (12)
A trial of autologous plasma perfusion over protein A in patients with breast cancer. (1984) (12)
Monoclonal antibody therapy of leukaemias and lymphomas (2005) (12)
Monoclonal antibody therapies for lymphomas. (2000) (12)
Generation of Her-2/neu vaccine utilizing idiotypic network cascade (2007) (12)
Immunologic classification of lymphoma and lymphoid leukemia. (1987) (12)
Idiotype vaccines in the clinic (1998) (12)
Expression of Ia-like antigens in human erythroid progenitor cells as determined by monoclonal antibodies and heteroantiserum to Ia-like antigens. (1981) (11)
Gemtuzumab ozogamicin as first‐line treatment in patients aged 70 years or older with acute myeloid leukemia (2010) (11)
Unusual gastrointestinal complications of interleukin-2 therapy. (1991) (11)
Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy. (2011) (11)
Staging and therapy of chronic lymphocytic leukemia. (1987) (11)
Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. (2001) (11)
Interferon therapy for lymphoproliferative disorders. (1988) (10)
Is there a T-cell form of chronic lymphocytic leukemia? (1992) (10)
Carcinoembryonic Antigen Transgenic Mouse Models for Immunotherapy and Development of Cancer Vaccines (2008) (10)
Laboratory and clinical applications of monoclonal antibodies for leukemias and non-Hodkin's lymphoma (1989) (10)
Human Antiglobulin Responses (2005) (10)
A MONOCLONAL ANTIBODY RECOGNIZING HUMAN THY‐ 1: DISTRIBUTION ON HUMAN AND NON‐HUMAN PRIMATE HAEMATOPOIETIC CELLS (1984) (10)
An antigen expressed by cells of the myelo‐monocytic lineage (1981) (9)
Biologic response modifiers: therapeutic approaches to lymphoproliferative diseases. (1992) (9)
Ex vivo activated monocytes and adoptive immunotherapy trials in colon cancer patients. (1986) (9)
Phase II study of short course CHOP-rituximab (R) followed by ibritumomab tiuxetan (IT) as first-line treatment for follicular lymphoma (FL) (2007) (9)
Immunotherapy for colorectal cancer (2001) (9)
Detection of differentiation antigens by use of monoclonal antibodies. (1981) (9)
Monoclonal antibodies in the treatment of cancer: Preliminary observations and future prospects (1984) (8)
Monoclonal antibodies to human colorectal tumor-associated antigens: improved elicitation and subclass restriction. (1984) (8)
Therapeutic options in advanced cutaneous T cell lymphomas: a role for interferon alfa-2a (Roferon-A). (1985) (8)
An antithymocyte serum noncytotoxic to myeloid progenitor cells: candidate serum for prevention of graft-versus-host disease in bone marrow transplantation. (1980) (8)
Preclinical and Clinical Evaluation of a Monoclonal Antibody to a Human Melanoma-Associated Antigen (1985) (8)
Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706 (2005) (8)
The treatment of cancer patients with human lymphoblastoid interferon (2004) (8)
The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas (2007) (8)
NK cells in cancer immunotherapy: three decades of discovery. (2006) (7)
Cancer Vaccines: Activating the Immune System to Fight Cancer (2008) (7)
Optimal strategies for developing human-human monoclonal antibodies. (1986) (7)
A Randomized Controlled Trial of Spiritually-Focused Meditation In Patients Newly Diagnosed with Acute Leukemia. (2010) (7)
Treatment of acute myelogenous leukemia in older patients. (1981) (7)
Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low‐grade follicular lymphomas (2002) (6)
Interferon use in solid tumors. (1998) (6)
Monoclonal antibody characterization of plasmacytoma cells associated with T lymphocytes with a suppressor phenotype. (1982) (6)
Histiocytic lymphoma following resolution of sarcoidosis. (1981) (6)
Monoclonal Antibody Therapy for Patients with Leukemia and Lymphoma (1985) (6)
Improved imaging of metastatic melanoma with high dose 9. 2. 27 In-111 monoclonal antibody (1985) (5)
Evaluation of alternative methodologies for the generation of murine monoclonal anti-idiotypic antibodies to human B cell leukemias and lymphomas. (1986) (5)
Translational Research: Advancing Medical Science by Stimulating Interdisciplinary Research (2007) (5)
Natural killer cells: from bench to cancer therapy (2006) (5)
The immunological classification of leukaemia based on a rapid microcytotoxicity test. (1982) (5)
Clinical transformation of chronic lymphocytic leukemia. (1988) (5)
Sclerodactyly in a patient with mycosis fungoides. (1985) (4)
Monoclonal antibody to human eosinophils recognizing 95 kD surface membrane antigen. (1983) (4)
Clinical applications of monoclonal antibodies for patients with leukemia and lymphoma. (1986) (4)
The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity. (1992) (4)
Idiotype manipulation in disease management. (1995) (4)
Laboratory and clinical applications of monoclonal antibodies for leukemias and non-Hodgkin's lymphomas. (1989) (4)
Posttransfusion Hepatitis in Acute Myelogenous Leukemia-Reply (1981) (4)
Two new monoclonal antibodies to human monocytes and granulocytes: isolation of membrane antigens and lack of effects of antibodies on leukocyte functions in vitro. (1984) (4)
CLINICAL RESPONSE TO ANTI-IDIOTYPE MONOCLONAL ANTIBODY VACCINE THERAPY FOR PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (1993) (3)
Mechanisms of Suppression Used by Regulatory T Cells in Patients Newly Diagnosed with Acute Myeloid Leukemia (2008) (3)
ACTIVE IMMUNITY TO THE CARCINOEMBRYONIC ANTIGEN (CEA) IN PATIENTS TREATED WITH AN ANTI-IDIOTYPE MONOCLONAL ANTIBODY VACCINE (1994) (3)
A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR2 Regimen (2014) (3)
Immunotherapy of gynecologic malignancies. (1990) (3)
Immunologic approaches to the classification of lymphomas and lymphoid leukemias. (1988) (3)
A Phase I Trial of Immune Interferon (1984) (3)
Biotherapy of cancer with interleukin-2, colony-stimulating factors, and monoclonal antibodies. (1988) (3)
Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2 induced protective antitumor immunity in mice transgenic for human Her-2 (2008) (2)
MAGNIFY: A phase 3B, randomized trial of lenalidomide plus rituximab induction and maintenance therapy followed by lenalidomide single-agent versus rituximab maintenance in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL). (2014) (2)
Early Clinical and Pharmacokinetic Results of Lower Dose Fludarabine and Cyclophosphamide, and High Dose Rituximab (FCR-Lite) for Patients with Untreated Chronic Lymphocytic Leukemia (CLL). (2006) (2)
Localization of yttrium 90 ibritumomab tiuxetan (90Y IT) in patients with CD20 + non-Hodgkin's lymphoma (NHL) (2005) (2)
Current status of interferon therapy in oncology. (1987) (2)
Cellular Localization Pattern of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in a Patient with Low-Grade Non-Hodgkin’s Lymphoma (NHL). (2004) (2)
Imaging results after CHOP-rituximab followed by 90Y ibritumomab tiuxetan and rituximab (R) in patients with previously-untreated follicular lymphoma (FL). (2006) (2)
Anti-Idiotype Vaccines (2004) (2)
Prognostic testing patterns in CLL pts treated in U.S. practices from the Connect CLL registry. (2015) (2)
Immunolymphoscintigraphy with Indium-111 labeled T101 monoclonal antibody (1985) (2)
Phase II Study of Short Course CHOP-Rituximab Followed by 90-Y Ibritumomab Tiuxetan as First-Line Treatment for Follicular Lymphoma: An Update and Extension of Preliminary Findings on Predictors of Relapse. (2008) (2)
IDEC-C2B8: INITIAL PHASE II RESULTS IN PATIENTS WITH B-CELL LYMPHOMA (1994) (2)
Therapeutic Anti-clonotypic Vaccines (1993) (2)
The generation of stable human T-cell hybridomas which constitutively produce interleukin-2 and chemotactic factor. (1985) (2)
Measurements of human anti murine antibodies in patients who received radiolabeled monoclonal antibodies (1986) (1)
Advances of immunotherapy of cancer: monoclonal antibodies and interferon. (1988) (1)
Daunorubicin or doxorubicin in acute myelogenous leukemia? (1988) (1)
Immunity in CEA Transgenic Mice Immunological Tolerance to CEA and Induce Antitumor Mimicking Carcinoembryonic Antigen ( CEA ) Can Reverse Dendritic Cells Pulsed with an Anti-Idiotype Antibody (2004) (1)
PS1253 MAGNIFY: PHASE IIIB INTERIM ANALYSIS OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA (2019) (1)
Final Results of Lower Dose Fludarabine (F) and Cyclophosphamide (C), and High Dose Rituximab (R), (FCR-Lite) for Patients with Untreated Chronic Lymphocytic Leukemia (CLL). (2007) (1)
Erratum: Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen (Immunology (2006) 118, (483-496)) (2006) (1)
A randomized prospective trial of the benefit of postoperative radiotherapy in the treatment of single metastases to the brain (1998) (1)
A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group (2019) (1)
Dendritic cell based vaccines for immunotherapy of (2003) (1)
Pharmacokinetics of In-111 T101 (anti-CD5) monoclonal antibody in patients with cutaneous T-cell lymphoma (1993) (1)
Biological approaches to cancer therapy. (1987) (1)
Clearly defined response criteria evaluating treatment of CLL patients in clinical research trials. (2010) (1)
Immunoglobulin Heavy Chain (IgH) Gene Somatic Hypermutation Status Using Homoduplex-Separated RT-PCR Products. (2004) (1)
Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders: BCL2 as a prognostic marker (2007) (1)
Functional properties of subsets of T lymphocytes defined by specific antigens. (1981) (1)
Increased frequency and suppressive function of CD4+ CD25high regulatory T-cells in acute myeloid leukemia patients (2007) (1)
Imaging of cutaneous T cell lymphoma (CTCL) with In-111-T101 monoclonal antibody (1985) (1)
Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy (2011) (1)
Efficacy of Mitoxantrone and Etoposide in Patients with Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy. (2007) (1)
Inadvertent overdose with lomustine (CCNU) followed by hematologic recovery. (1982) (1)
The role of E2A in B cell chronic lymphocytic leukemia (2008) (1)
Anti-Idiotype Antibody Vaccines for the Immunotherapy of Cancer (2006) (1)
Clinical and immune responses in metastatic melanoma patients immunized with an anti-idiotype (anti-Id) monoclonal antibody (mAb) mimicking disialoganglioside gd21 (1999) (1)
Clinical Aspects of Interferon Therapy in Human Cancer (1988) (0)
Therapeutic Applications of Monoclonal Antibodies for Lymphoma and Leukemia (1988) (0)
Anti-idiotypic Monoclonal Antibodies: Novel Approach to Immunotherapy (1994) (0)
Considerations in the diagnosis and therapy of human T-cell lymphoma with monoclonal antibodies (1989) (0)
Biotherapy with interferon in hematologic malignancies. (1987) (0)
Interleukin-15 Upregulates the Expression of NK-Cell Activating Receptors and Concomitantly Increases the NK Cytotoxicity in Patients with Acute Myeloid Leukemia. (2007) (0)
Erratum (2006) (0)
Monoclonal Antibody Therapy for Hematologic Malignancies (2010) (0)
Monoclonal antibody therapy of lymphomas and leukemia. (1988) (0)
MAGNIFY: A randomized, phase 3b trial in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) investigating lenalidomide plus rituximab (R2) induction followed by maintenance R2 followed by lenalidomide versus R2 induction followed by rituximab (R) maintenance. (2015) (0)
Targeted knockdown of the B lineage transcriptional activator E2A in B cell chronic lymphocytic leukemia (CLL) enhances lenalidomide sensitivity and regulates cellular proliferation (88.7) (2009) (0)
Treatment of cutaneous T-cell lymphomas with biologic response modifiers: Recombinant leukocyte A interferon and T101 monoclonal antibody (1985) (0)
encoding for multiple costimulatory molecules (CLL): enhanced immunogenicity of CLL cells via infection with vectors Potential approach to immunotherapy of chronic lymphocytic leukemia (2013) (0)
Human Alveolar Macrophages Express (2005) (0)
8th Annual San Antonio Breast Cancer Symposium Biological therapy of cancer (1986) (0)
The Role of Interleukin-15 on Natural Killer Cell Homeostasis and Activity in Patients with Acute Myeloid Leukemia (2008) (0)
Antigenic characteristics of normal and malignant human hematopoietic cells. Potential use of antigenic differences in cell separation and marrow transplantation. (1979) (0)
Clinical a nd I mmune R esponses i n R esected C olon C ancer Patients T reated W ith A nti-Idiotype M onoclonal A ntibody Vaccine T hat M imics t he C arcinoembryonic A ntigen (1999) (0)
Up-regulation of natural killer (NK) cell activating receptors and increase in NK mediated cytotoxicity using interleukin-15 in patients with newly diagnosed acute myeloid leukemia (AML) (2008) (0)
that is selectively expressed in B-lymphoid cells and B-CLL The PANE1 gene encodes a novel human minor histocompatibility antigen (2013) (0)
Modification of B-CLL Cells Via Infection with a Replication-Defective MVA Virus Encoding Three Costimulatory Molecules: A Potential Approach to Tumor Cell Immunotherapy of B-CLL. (2004) (0)
Nasopharyngeal Cervical cancer Hematological malignancies Hairy cell leukemia * Non-Hodgkin ' s lymphoma Low grade Intermediate and high grade Hodgkin ' s disease Cutaneous T-cell lymphoma Chronic lymphocytic leukemia Multiple myeloma Chronic myelogenous leukemia (2006) (0)
Serotonin (5 hydroxytryptamine) induced lymphokine production from human peripheral blood lymphocytes (1975) (0)
259 Induction of anti-tumor immunity by an anti-idiotype antibody mimicking human HER2/Neu (2004) (0)
Generation of alpha-Type-1 Polarized Dendritic Cells as a Potent Immunogen in Patients with Chronic Lymphocytic Leukemia. (2007) (0)
Commentary (Grandis/Foon): Emerging Role of EGFR-Targeted Therapies and Radiation in Head and Neck Cancer (2004) (0)
Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. (1982) (0)
Biological therapies: Twenty-five years of progress in cancer therapy (2006) (0)
Interferon therapy of hematologic malignancies. (1998) (0)
Biological Approaches to the Therapy of Lymphoproliferative Diseases (1985) (0)
Anti-ldiotype Antibodies: Novel Therapeutic Approach to Cancer Therapy (2020) (0)
Results of a Multi-Center, Phase II Study of Elsamitrucin (SPI-28090) in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma (NHL). (2005) (0)
Immunotherapy of Cancer Patients with Anti-Idiotype Vaccines (1997) (0)
An administrative structure for integration of multimodality image implementation and tumor-metric analysis for early assessment of therapeutic response in cancer by Image Response Assessment Teams (IRAT) (2008) (0)
CD4+ CD25high Regulatory T Cells in Newly Diagnosed Patients with Acute Myeloid Leukemia. (2007) (0)
A monoclonal antibody recognizing human thy-1: distribution on normal and malignant hematopoietic cells. Abstr. (1981) (0)
Lymphocytic leukemias: new insights into biology and therapy. (1992) (0)
Vaccine Strategies for Colorectal Cancer (2002) (0)
An Alternative Transcript of the PANE1 Gene Encodes a Minor Histocompatibility Antigen That Is Selectively Expressed in Resting CD19+ Cells and B-CLL. (2005) (0)
P12 Immune responses in melanoma patients immunized with an anti-idiotype (Id) antibody mimicking GD2 (1999) (0)
Methods and Compositions for the Treatment of Psoriasis (2017) (0)
Chronic Lymphocytic Leukemia (2020) (0)
3H1 monoclonal antibody-murine anti-id. (1995) (0)
Fate of 7-Interferon-activated Killer Blood Monocytes Adoptively Transferred into the Abdominal Cavity of Patients with Peritoneal Carcinomatosi* (2006) (0)
Methods of Delaying Development of CEA-Associated Tumors Using Anti-Idiotype Antibody 3H1 (2017) (0)
Interferon Therapy of Chronic Lymphocytic Leukemia and Viral Infections in Leukemia Patients (1988) (0)
Early results of modified fludarabine, cyclophosphamide, and rituximab (mFCR) for patients with previously untreated advanced chronic lymphocytic leukemia (CLL). (2006) (0)
Localization of 111 ln-and 125 l-labeled Monoclonal Antibody in Guinea Pigs Bearing Line 10 Hepatocarcinoma Tumors 1 (2006) (0)
Advances in cancer: monoclonal antibody therapy of hematologic malignancies. (1987) (0)
Anti-idiotype antibodies: novel therapeutic approach to cancer therapy. (1994) (0)
Monoclonal anti-idiotype antibody 3h1 from mouse (1995) (0)
Clinical a nd I mmune R esponses i n A dvanced M elanoma Patients I mmunized W ith a n A nti-Idiotype A ntibody Mimicking D isialogangliosi de G D2 (2000) (0)
Treatment of Leukemia and Lymphoma with Biological Response Modifiers (1985) (0)
CpG DNA augments dendritic cell-based therapy of colon cancer in transgenic mice (48.21) (2007) (0)
Interferon therapy of lymphoproliferative disorders. (1986) (0)
A Phase I/II Study of Reduced Dose FCR (FCR-lite) in Combination with Lenalidomide Followed By Lenalidomide Maintenance (FCR2) for Initial Therapy of CLL: Final Results and Long-Term Follow-up (2017) (0)
Improved utilization of molecular imaging for response assessment in oncologic clinical trials by the University of Pittsburgh Imaging Response Assessment Teams (2007) (0)
Human Alveolar Macrophages Express Ia (2005) (0)
Aqueous Humor During Experimental Immunogenic Uveitis (0)
New Therapeutic Options for Chronic Lymphocytic Leukemia (2007) (0)
Growth inhibitory effect of supernatants obtained from peripheral mononuclear cells primed with anti-CD 3 Ab and r-interleukin 2 (1993) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Kenneth A. Foon?

Kenneth A. Foon is affiliated with the following schools:

Kenneth A. Foon's Academic­Influence.com Rankings

Kenneth A. Foon's Degrees

Why Is Kenneth A. Foon Influential?

Kenneth A. Foon's Published Works

Published Works

What Schools Are Affiliated With Kenneth A. Foon?

Kenneth A. Foon's AcademicInfluence.com Rankings